Compare IMMP & ONMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IMMP | ONMD |
|---|---|---|
| Founded | 1987 | 2006 |
| Country | Australia | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 31.5M | 31.3M |
| IPO Year | 2012 | 2021 |
| Metric | IMMP | ONMD |
|---|---|---|
| Price | $3.36 | $4.80 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 30.6K | 21.5K |
| Earning Date | 09-01-2026 | 11-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 83.33 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,359,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 111.35 |
| 52 Week Low | $0.26 | $0.63 |
| 52 Week High | $5.36 | $115.00 |
| Indicator | IMMP | ONMD |
|---|---|---|
| Relative Strength Index (RSI) | 49.75 | 37.47 |
| Support Level | $3.06 | $3.86 |
| Resistance Level | $3.55 | $4.99 |
| Average True Range (ATR) | 0.34 | 0.57 |
| MACD | -0.05 | 0.37 |
| Stochastic Oscillator | 41.09 | 22.66 |
Immutep Ltd is a clinical-stage biotechnology company developing novel Lymphocyte Activation Gene-3 (LAG-3) related immunotherapies for cancer and autoimmune disease. It has a diversified product portfolio that harnesses LAG-3's ability to stimulate the body's immune response to fight cancer or suppress the immune system to treat autoimmune disease. The company is focused on advancing its product candidate, eftilagimod alfa (efti), through its registrational Phase three clinical trial towards marketing approval in first-line non-small cell lung cancer (1L NSCLC). The other product candidates in its portfolio include TACTI-003, AIPAC-003, TACTI-002, INSIGHT-005, and others, being developed as potential therapies for various cancers and autoimmune diseases.
OneMedNet Corp is a healthcare software company with solutions focused on digital medical image management, exchange, and sharing. It is a provider of clinical imaging innovation and curator of regulatory-grade Imaging Real World Data(iRWDTM). Its solutions connect healthcare providers and patients, satisfying a crucial need within the life sciences field, offering direct access to clinical images and the associated contextual patient record. Its technology has provens the commercial and regulatory viability of imaging Real World Data, an emerging market, and provides regulatory-grade, image-centric iRWDTM. Geographically, it operates in Americas, Europe and Middle East, and Asia Pacific. It derives maximum revenue from Europe and Middle East.